Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorUniversity of Wisconsin, Madison
About this trial
This study aims to investigate whether a novel artificial intelligence based screening strategy (AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education or AI-BRIDGE), which allows primary care providers to screen patients for vision-threatening diabetic eye disease in the primary care clinic, improves screening and follow-up care rates across race/ethnicity groups and reduces racial/ethnic disparities in screening.
Eligibility criteria
Qualifiers
Diagnosed with type 1 or 2 diabetes
No known diabetic eye disease
Medicaid as their primary insurance
Not had an eye exam in the prior year
Disqualifiers
None
Trial design
Treatments tested in this trial
- AI
Treatment groups
4,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Wisconsin, Madison
Lead sponsor
National Eye Institute (NEI)
Collaborator
Source ClinicalTrials.gov